Elekta has secured a loan of up to €100m to support a roughly €200m research programme focused on cancer and neurological treatment technologies.
The Stockholm-based medical technology company plans to carry out the research programme between 2026 and 2029, with most of the work based in Sweden and the Netherlands.
The financing will support work across radiotherapy, radiosurgery, brachytherapy and software used to plan and deliver these treatments.
Elekta’s research will focus on treatments for conditions including tumours in the brain and body, essential tremor and certain forms of epilepsy.
The company says its work is intended to make treatments more accurate and efficient while helping healthcare providers treat growing numbers of cancer patients.
Founded in 1972 by Lars and Laurent Leksell, Elekta develops precision radiation medicine for cancers including brain tumours, breast, kidney, lung, pancreatic and prostate cancer, as well as certain neurological disorders.
The company says its technology treats more than 2m patients each year. It employs around 4,000 people, has offices in more than 40 countries and sells into more than 120 markets.
Klara Eiritz, chief financial officer at Elekta, said: “As demand for cancer care continues to grow, healthcare providers are looking for solutions that help them treat more patients while maintaining quality and precision.
“This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience.”
The loan is being provided by the European Investment Bank, the European Union’s financing arm, and will cover up to half of Elekta’s roughly €200m research programme.
The financing falls under the EIB Group’s TechEU programme, which is designed to strengthen European investment in strategic technologies and innovation.
Karl Nehammer, vice-president at the EIB, said: “Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here. This financing will support the next generation of cancer and neurological treatments.”
